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Abstract
As a central element within the RAS/ERK pathway, the serine/thre-
onine kinase BRAF plays a key role in development and homeosta-
sis and represents the most frequently mutated kinase in tumors.
Consequently, it has emerged as an important therapeutic target
in various malignancies. Nevertheless, the BRAF activation cycle
still raises many mechanistic questions as illustrated by the para-
doxical action and side effects of RAF inhibitors. By applying
SEC-PCP-SILAC, we analyzed protein–protein interactions of hyper-
active BRAFV600E and wild-type BRAF (BRAFWT). We identified two
macromolecular, cytosolic BRAF complexes of distinct molecular
composition and phosphorylation status. Hyperactive BRAFV600E
resides in large complexes of higher molecular mass and activity,
while BRAFWT is confined to smaller, slightly less active complexes.
However, expression of oncogenic K-RasG12V, either by itself or in
combination with RAF dimer promoting inhibitors, induces the
incorporation of BRAFWT into large, active complexes, whereas
pharmacological inhibition of BRAFV600E has the opposite effect.
Thus, the quaternary structure of BRAF complexes is shaped by its
activation status, the conformation of its kinase domain, and
clinically relevant inhibitors.
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Introduction
The ARAF, BRAF, and CRAF kinases play a central role in physio-
logical and pathological conditions by controlling cell fate decisions
such as proliferation, differentiation, and survival. BRAF is the most
frequently mutated kinase in tumors with particularly high frequen-
cies in low-grade astrocytoma, melanoma, and hairy cell leukemia
(Ro¨ring & Brummer, 2012; Samatar & Poulikakos, 2014). Further-
more, BRAF mutant colorectal carcinoma (CRC) with microsatellite
stability represents the most aggressive sub-entity (see Herr et al,
2015 and references therein).
Consequently, BRAF has become an important therapeutic target
in cancer (Holderfield et al, 2014; Turski et al, 2016), with other
proliferative diseases such as RASopathies and polycystic kidney
disease potentially following suit, as it has been suggested by animal
models (Inoue et al, 2014; Chang et al, 2015). The clinically most
advanced compounds, vemurafenib or dabrafenib, as well as the
first RAF inhibitor sorafenib are ATP competitive drugs. Indeed,
vemurafenib and dabrafenib have significantly improved the treat-
ment options for metastatic melanoma harboring BRAFV600E/K muta-
tions (Chapman et al, 2011; Hauschild et al, 2012) and similar
outcomes may be achieved in other malignancies driven by
BRAFV600E such as hairy cell leukemia (Dietrich et al, 2016). Never-
theless, even initially responding BRAF mutant melanomas acquire
drug resistance (Moriceau et al, 2015). Moreover, other tumor enti-
ties such as CRC do not display such uniform responses due to
primary resistance caused by rapid reactivation of the EGFR path-
way (Corcoran et al, 2012; Prahallad et al, 2012). This insight led to
the development of clinical trials combining multiple targeted
therapy compounds.
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Indeed, many of the recently documented inhibitor resistance
mechanisms can be linked to the intricate feedback regulation of the
ERK pathway (Sturm et al, 2010; Fritsche-Guenther et al, 2011; Lito
et al, 2012) and the paradoxical behavior of RAF inhibitors
(Hatzivassiliou et al, 2010; Heidorn et al, 2010; Poulikakos et al,
2010). Although the precise mode of action is still under debate, the
latter phenomenon relies on the presence of active GTP-loaded RAS
and the formation of BRAF homo- or heterodimers (Ro¨ring &
Brummer, 2012; Lavoie & Therrien, 2015). Based on the observation
that an intact dimer interface (DIF) is required for the paradoxical
action of kinase-inhibited BRAF molecules (Ro¨ring et al, 2012), it
can be anticipated that binding of the inhibitor to one RAF molecule
locks this protomer into a conformation in which it can transactivate
the drug free protomer of the dimer by an allosteric mechanism.
The paradoxical action of RAF inhibitors is of high clinical
relevance as it: (i) precludes the use of selective BRAF inhibitors in
RAS mutant tumors highlighting the need to stratify cancer patients
prior to drug administration (Holderfield et al, 2014; Samatar &
Poulikakos, 2014), (ii) contributes to acquired drug resistance, for
example, by positively selecting tumor cells with secondary muta-
tions or amplifications in RAS or receptor tyrosine kinase genes
(Ro¨ring & Brummer, 2012; Straussman et al, 2012; Ahronian et al,
2015; Moriceau et al, 2015), and (iii) by promoting secondary
neoplasms (Callahan et al, 2012; Su et al, 2012; Yaktapour et al,
2014; Carlino et al, 2015; Dietrich et al, 2016). These limitations of
RAF inhibitors highlight the need for better understanding of normal
and mutant BRAF signaling at the molecular level, in particular of
the composition and regulation of BRAF signaling complexes during
the activation cycle of the kinase.
Indeed, the BRAF activation cycle remains incompletely under-
stood. So far, it has emerged that activation of BRAF is triggered by
its interaction with GTP-loaded RAS proteins and is accompanied by
changes in its phosphorylation status and protein interaction reper-
toire, including the formation of homo- and/or heterodimers
(Baljuls et al, 2013; Cseh et al, 2014) and the interaction with the
HSP90/CDC37 complex (Jaiswal et al, 1996; Vaughan et al, 2006).
The phospho-serine binding proteins of the 14-3-3 family regulate
various steps of the activation cycle by either stabilizing the closed,
inactive conformation of BRAF, or by promoting dimerization and
downstream signaling. This dual role of 14-3-3 is reflected by the
observations that alanine substitution of the C-terminal 14-3-3 bind-
ing site S729 abolishes BRAF activity (except for BRAFV600E),
whereas that of the N-terminal motif around S365 increases kinase
activity (MacNicol et al, 2000; Brummer et al, 2006; Rodriguez-
Viciana et al, 2006; Hmitou et al, 2007; Fischer et al, 2009; Ritt
et al, 2010). Furthermore, mutations of the RDRSSS365AP motif,
likely interfering with S365 phosphorylation and/or 14-3-3 binding,
have been found in tumors, further highlighting its relevance for
negative regulation (Eisenhardt et al, 2016).
Numerous, mostly ill-defined kinases mediate feed-forward and
-back phosphorylation of BRAF by upstream activators and down-
stream effectors, respectively. For example, wild-type BRAF
(BRAFWT) is stringently controlled by RAS-dependent phosphoryla-
tion-induced conformational change of its activation loop (Zhang &
Guan, 2000). This in turn restructures its catalytic center, leading to
DIF exposure, allosteric transactivation and ultimately the genera-
tion of a fully active BRAF signaling complex (Wan et al, 2004; Hu
et al, 2013; Thevakumaran et al, 2015; Ko¨hler et al, 2016). The
most prevalent oncogenic BRAF mutation, V600E, mimics activation
loop phosphorylation and locks the kinase in an active conforma-
tion by forming a mutation-specific salt-bridge, thereby causing a
short-circuit in the activation cycle and leading to chronic MEK/ERK
signaling (Wan et al, 2004). Thus, V600E bypasses several steps
required for the activation of BRAFWT such as N-region phosphory-
lation, RAS, and 14-3-3 binding and dimerization, but also renders
the oncoprotein resistant to negative regulation (Tsavachidou et al,
2004; Emuss et al, 2005; Brummer et al, 2006; Brady et al, 2009;
Fischer et al, 2009; Poulikakos et al, 2011; Ro¨ring et al, 2012;
Freeman et al, 2013).
The homo- and hetero-dimerization of BRAF is highly relevant
for drug action: Firstly, tumor-associated N-terminally truncated
BRAF proteins, which have lost large portions of the regulatory
regions required for auto-inhibition and consist merely of the kinase
domain, display increased activity and homo-dimerization potential.
The latter also confers an intrinsic resistance toward vemurafenib
and sorafenib. Importantly, these proteins can be re-sensitized to
these drugs by a point mutation in the DIF, suggesting that rather
the quaternary structure of the BRAF complex than the altered
BRAF tertiary structure determines drug binding (Poulikakos et al,
2011; Sievert et al, 2013; Karajannis et al, 2014; Karoulia et al, 2016).
To comprehensively study BRAF activation, the rewiring of
protein–protein interactions of BRAFWT and BRAFV600E and their
role in cell transformation and paradoxical ERK activation, we
globally analyzed macromolecular, cytosolic protein complexes by
a combination of size exclusion chromatography and mass spec-
trometry (Kristensen et al, 2012). We characterized discrete
macromolecular BRAF complexes of distinct composition. Their
differences in activity and interaction partners were linked to
altered phosphorylation patterns. Our data show that, in contrast
to previous concepts, the interactions of wild-type and oncogenic
BRAF with 14-3-3 proteins and the HSP90/CDC37 complex are
dynamically regulated, explaining among others the observation
that BRAF mutant tumors are sensitive to clinically relevant HSP90
inhibitors, and outlining strategies for combination therapies.
Results
BRAF expression levels do not influence overall
protein abundances
To study the influence of BRAF variants on the composition of
macromolecular cytosolic protein complexes, we used CaCo-2 subli-
nes fitted with a doxycycline (Dox)-inducible expression system of
either hemagglutinin (HA)-tagged BRAFWT or BRAFV600E (Herr et al,
2011; Ro¨ring et al, 2012). These CaCo-2tet cells are derived from a
colon adenocarcinoma and lack BRAF or KRAS mutations and thus
represent an ideal model system to study CRC-associated oncogenes
in the context of colonic epithelium (Herr et al, 2015). Cells were
treated with Dox for up to 96 h, and protein abundances were
analyzed by immunoblotting (Fig 1A). After 6–12 h, HA-BRAF
could be detected and cells responded with an increase in phospho-
MEK and phospho-ERK levels (Fig 1B), with BRAFV600E inducing a
faster response and a differential of more than ninefold. Importantly,
MEK levels stayed relatively constant over the timeframe of treat-
ment. Interestingly, the differential in MEK/ERK phosphorylation
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elicited by BRAFV600E compared to BRAFWT became less pronounced
with increasing induction time. The exact reason for this phenom-
enon is unknown, but could be potentially explained by the afore-
mentioned feedback phenomena. The reduced Western blot signal of
MEK compared to phospho-MEK is due to a phosphorylation-
dependent decrease in antibody reactivity (Appendix Fig S1). After
48 h of Dox treatment, BRAF levels were stable, indicating a steady
state. This also applied for downstream signaling pathways. There-
fore, in all following experiments, oncogene expression was induced
for 48 h. The advantage of the CaCo-2tet system is that experiments
addressing the influence of potent oncogenes on protein homeostasis
can be carried out in an isogenic background. However, overexpres-
sion may also lead to artifacts. To exclude that BRAF expression
globally alters protein abundances, we compared BRAF-expressing
cells with vector control cells also being treated with Dox by SILAC-
based proteomics (Fig 1C). In total, 1,945 proteins were quantified.
BRAF itself was approximately ninefold enriched in the BRAF-
expressing cell lines. All other proteins exhibited normal distribu-
tions with 95% of proteins showing maximally a twofold difference
in abundance. Importantly, abundances of known and novel BRAF
interactors identified in this study, like the 14-3-3 and HSP90
proteins, NRAS, KRAS, and MEKs did not differ in cells ectopically
expressing HA-BRAF variants (Fig 1D, Appendix Fig S1). Overex-
pression of either wild-type or oncogenic BRAF does neither alter
global protein abundances nor abundances of proximal up- and
down-stream BRAF signaling partners. In that regard, it should be
noted that even higher increases in BRAF protein expression occur
in response to drug exposure in vitro and in patients, indicating that
this degree of overexpression of BRAF in our Caco-2tet system is
relevant (Little et al, 2011; Moriceau et al, 2015). Thus, the
influence of BRAFWT and BRAFV600E expression on macromolecular
protein dynamics can be studied in an inducible, isogenic cell system
with relevance to colon cancer.
Analysis of cytosolic macromolecular protein complexes
by SEC-PCP-SILAC
To comprehensively characterize the global interactome in HA-
BRAFWT and HA-BRAFV600E-expressing cells, we applied SEC-PCP-
SILAC, which combines native size exclusion chromatography with
quantitative proteomics (Kristensen et al, 2012; Kirkwood et al,
2013). CaCo-2tet cells were SILAC labeled and HA-BRAF expression
was induced for 48 h by Dox addition (Fig 2A). A mixture of light-
labeled cells expressing BRAFWT and BRAFV600E served as a control
to identify cytosolic complexes in heavy-labeled BRAFWT and
medium-heavy-labeled BRAFV600E-expressing cells, respectively.
From the acquired data, the identified proteins engaged in interac-
tions are observed as strongly co-eluting (Fig 2B), and by hierarchi-
cal clustering (Fig 2C), a landscape of protein interactions and
complexes was obtained (Fig 2D; see Materials and Methods for
details). We performed three biological replicates with swapped
SILAC labels and found a good reproducibility of protein elution
profiles between all replicates (Fig 2E; median correlation coeffi-
cient of 0.65). Combining the data from all replicates, we extracted
3,739 binary interactions of 555 proteins after stringently filtering
the data and requiring the interaction to be observed in at least two
replicates (Appendix Fig S2, Dataset EV1; MS raw data can be found
in PRIDE DB; Vizcaino et al, 2016, dataset identifier PXD004585).
The inferred interactions could be clustered into 77 clusters
representing potential complexes (Dataset EV2; Nepusz et al, 2012).
A
B
C D
Figure 1. Isogenic cell system employed to study the effects of BRAFWT and BRAFV600E on the composition of cytosolic macromolecular protein complexes.
A The time-dependent effect of HA-BRAFWT (WT) and HA-BRAFV600E (V600E) expression in CaCo-2 cells is monitored by Western blot. Expression of HA-tagged fusion
constructs is induced for the annotated timeframes by the addition of doxycycline (Dox). Effects of oncogene expression are monitored by the abundance of the
downstream target sites pMEK and pERK. Vertical line indicates two separately blotted gels.
B Quantifications of blots shown in panel (A) normalized to the GAPDH signal.
C To analyze effects of oncogene overexpression on global protein abundance, SILAC-labeled cells overexpressing WT and V600E are compared to Dox-treated
unlabeled vector control cells (ctrl). Histograms highlight detected protein numbers. BRAF is marked in red.
D Abundance differences of known and newly identified BRAF binding partners are shown comparing WT- and V600E-expressing cells with vector control cells. Red line
indicates levels in vector control cells. Error bars indicate standard deviation.
Source data are available online for this figure.
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Upon inspection, we could reconstitute many of the major cytosolic
complexes from the list of observed complexes. This demonstrates
that SEC-PCP-SILAC is suitable for obtaining an unbiased overview
of protein–protein interactions (Fig 2F).
BRAFWT and BRAFV600E localize to discrete protein complexes
To identify proteins that change their interactions in response
to oncoprotein induction, we compared HA-BRAFWT and
HA-BRAFV600E-expressing cells and plotted the sum of squared dif-
ferences of SEC-PCP-SILAC ratios of three biological replicates
(Fig 3A). To our surprise, the protein exhibiting the most robust
change across the fractions was BRAF itself. Indeed, SEC-PCP-SILAC
profiles of HA-BRAFWT and HA-BRAFV600E differed tremendously
(Fig 3B). Whereas a large proportion of BRAFV600E localized to SEC
fractions 22–26 corresponding to a molecular weight of ~600 kDa
(Appendix Fig S3), the majority of BRAFWT was found in fractions
38–42, which harbored protein complexes of about 200 kDa. As the
A
D
F
B
E
C
Figure 2. SEC-PCP-SILAC workflow and data analysis.
A WT- and V600E-expressing cells are differentially SILAC labeled and lysed. Organelles and nuclei are removed by ultra-centrifugation and the cytosol is filtered.
Protein complexes larger than 100 kDa are separated by SEC. Fractions are mixed and combined with a light-labeled internal standard (Arg0/Lys0). Prior LC-MS/MS
analysis proteins are digested with trypsin.
B SEC-PCP-SILAC elution profiles of 60S (green, 26 proteins) and 40S (blue, 21 proteins) ribosomal subunits. Each line represents the elution profile of a specific protein
(see Datasets EV1 and EV2 for complete lists).
C Heatmap of normalized SILAC ratios of proteins identified from SEC fractions with each row corresponding to one individual protein. As an example, WT elution data
from replicate 1 are shown. SILAC protein ratios of WT proteins versus the internal standard were normalized to one, highlighting the relative abundance of a specific
protein in all SEC fractions. Rows are hierarchically clustered to show similar eluting protein groups.
D 3D visualization of filtered proteins showing the appearances of protein complexes as hills with proteins of similar intensity in the same fractions grouped together.
E Distribution of the Pearson correlation coefficients between the elution profiles for each protein in three biological replicates.
F Network diagrams of selected protein complexes inferred from the data. Edges indicate interactions and nodes indicate single proteins.
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elution profiles are stoichiometric, the area under the curve of the
two BRAFV600E complexes indicates that the high molecular weight
(MW) complex contains roughly one-third of cytosolic BRAFV600E
(Appendix Fig S3). In contrast, BRAFWT is present at much lower
levels in the high MW complex (Fig 3B).
This segregation into two distinctly sized BRAF complexes, as
defined by size exclusion chromatography, is reminiscent to our
previous blue native PAGE (BN–PAGE) experiments showing that
BRAFV600E is predominantly located in larger complexes (Ro¨ring
et al, 2012). The BN–PAGE approach, however, is very limited when
A
F
K L M
G H I J
B C D E
Figure 3. WT and V600E localize to discrete macromolecular protein complexes.
A To screen for proteins changing their interactions the differences in CaCo-2tet SEC-PCP-SILAC chromatograms are calculated. Only proteins with a value for the
sum of squared difference in all three replicates are considered. BRAF is marked.
B Overlay of SEC elution profiles for V600E and WT in replicate 1 are shown.
C–E Overlay of V600E and CDC37 (C), HSP90 (D), or 14-3-3 (E) elution profiles.
F Overlay of SEC elution profiles for BraffloxV600E; Rosa26::CreERT2 MEFs expressing either BRAFWT (EtOH) or BRAFV600E (4-HT) are shown.
G–I Overlay of V600E (4-HT) and CDC37 (G), HSP90 (H), or 14-3-3 (I) elution profiles.
J 14-3-3 proteins interact stronger with WT, CDC37 stronger with V600E as shown by anti-HA and anti-CDC37 IPs from CaCo-2 whole-cell lysate. CDC37 does not
directly interact with 14-3-3 proteins.
K, L (K) Western blot of CaCo-2 SEC fractions representing the high and low molecular weight complexes. 14-3-3 proteins are found predominantly in the low weight
fractions and CDC37 in the high weight fractions. 14-3-3 binding sites of BRAF are phosphorylated in the low weight fractions promoting BRAF–14-3-3 interaction
and less so in the high weight fractions as shown by phosphosite-specific Western blot and (L) mass spectrometry (n = 2).
M Plat-E cells were transiently transfected with indicated BRAF variants and complex distributions were analyzed by blue native (BN) PAGE followed by Western blot.
SDS–PAGE Western blots served as loading control.
Source data are available online for this figure.
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it comes to the identification of complex composition as antibodies
for potential candidates must be highly specific and able to recog-
nize their epitope in the non-denatured protein (Swamy et al, 2006).
In sharp contrast, SEC-PCP-SILAC enabled us now to analyze the
compositions of the high and low MW complexes in an unbiased
manner. Indeed, the analysis of known BRAF binding partners also
showed a surprising differential distribution. The chaperone HSP90
and its cofactor CDC37 were found in the high MW complex (Fig 3C
and D). On the contrary, 14-3-3 proteins (YWHAx) predominantly
localized to the low MW complex (Fig 3E).
To analyze whether the differential distribution of BRAFWT and
BRAFV600E and its binding partners can also be observed under
endogenous BRAF expression levels, we established murine embry-
onic fibroblasts (MEFs) from homozygous BraffloxV600E knock-in
mice (Dankort et al, 2007) carrying a Rosa26::CreERT2 allele
expressing a 4-hydroxytamoxifen (4-HT) inducible Cre recombinase
(Ventura et al, 2007). Prior to 4-HT exposure, these BraffloxV600E;
Rosa26::CreERT2 MEFs express BRAFWT from its own endogenous
promoter. Upon Cre activation, however, the mini-gene allowing the
expression of BRAFWT is excised from both alleles and the restored
reading frames encode BrafV600E instead (Dankort et al, 2007). We
performed SEC-PCP-SILAC analyses as described and also identified
high and low MW complexes depending on the expressed BRAF
variant (Fig 3F). Although elution profiles did not overlap comple-
tely as in the human CaCo-2 cells, BRAF binding partners showed a
similar differential distribution, with the larger complex being char-
acterized by CDC37 and HSP90 and the smaller by 14-3-3 proteins
(Fig 3G–I). Thus, the differential distribution of BRAFWT and
BRAFV600E complexes and their distinct composition is not confined
to ectopically expressed BRAF in human cells, but is also observed
for endogenous BRAF in murine cells.
The differential distribution of the HSP90 complex and 14-3-3
proteins between complexes and thus between BRAFV600E and
BRAFWT could also been shown by classical affinity purifications
targeting BRAF itself, as well as by reverse immunoprecipitation
(IP) targeting CDC37 (Fig 3J). CDC37 bound stronger to BRAFV600E
and we were not able to co-purify 14-3-3 proteins with CDC37. Mini-
mum binding of 14-3-3 proteins to BRAF is dependent on its phos-
phorylation at either Ser365 or Ser729, with the latter representing
the high affinity and major binding site (Brummer et al, 2006;
Fischer et al, 2009). In agreement with the differential distribution
of 14-3-3 proteins, we could show that both sites are highly phos-
phorylated in the low MW complex and hardly phosphorylated in
the high MW complex (Fig 3K and L). Importantly, the activation
status of BRAF appears critical for its allocation into either the small
or large complex, as the activating S365A mutation shifted the
majority of BRAFS365A molecules into the larger complex (Fig 3M).
Commensurate with earlier findings that the gain of function
imposed by the S365A mutation is offset by the S729A substitution
(Brummer et al, 2006; Fischer et al, 2009), a large proportion of
BRAFS365A/S729A proteins is found in the smaller complex again.
BRAFV600E/S729A, which has been previously shown to retain most
of its signaling capacity reacts less pronounced and stays in the larger
complex (Brummer et al, 2006; Fischer et al, 2009; Ritt et al, 2010).
To comprehensively study BRAF interactions and analyze the
distribution of binding partners between the macromolecular
complexes, we also characterized the interactomes of BRAFV600E
and BRAFWT by conventional IPs from CaCo-2 whole-cell lysate
using SILAC-based quantitative MS (Appendix Fig S4, Dataset EV3).
In two biological replicates, 32 significantly enriched binding part-
ners were identified (Fig 4A, P < 0.05, Benjamini–Hochberg (BH)
corrected). A network of 19 proteins could be constructed using
STRING DB (Fig 4B; Szklarczyk et al, 2015). As observed before,
HSP90 proteins and CDC37 were found at higher levels in
BRAFV600E precipitates. Furthermore, two novel interaction part-
ners, the aromatic hydrocarbon (AH) receptor-interacting protein
(AIP) and the peptidyl-prolyl cis-trans isomerase FKBP5 were also
found to interact more strongly with BRAFV600E. In contrast, 14-3-3
theta (YWHAQ) and epsilon (YWHAE) were found to associate
predominantly with BRAFWT. Of note, also the serine/threonine-
protein phosphatase 2A subunit B (PPP2R2A) and MEK (MAP2K1/2)
were more abundant in BRAFWT complexes. The latter finding is in
agreement with the fact that BRAFV600E leads to increased MEK
phosphorylation weakening the BRAFV600E–MEK interaction (Haling
et al, 2014). FKBP5 and PPP2R2A were also identified by SEC-PCP-
SILAC, and in agreement to the co-IP data, the elution profile of
FKBP5 indicates its interaction with the high MW complex, whereas
the elution profile of PPP2R2A identifies the phosphatase subunit as
a component of the low MW complex. This is true for CaCo-2 cells
ectopically expressing BRAF variants (Fig 4C and D) and for MEFs
endogenously expressing BRAF (Fig 4E and F). To further corrobo-
rate the differential distribution of BRAF binding partners to the
high and low MW complexes, we directly performed IPs out of SEC
fractions and analyzed protein abundances by label-free MS. As
expected, proteins found to associate more with one or the other
isoform of BRAF in the previous experiments could be observed as
enriched in the respective high and low MW complexes (Fig 4G and
H). For example, FKBP5, HSP90, and CDC37 were enriched in the
high MW complex, whereas PPP2RA, MEK, and all 14-3-3 proteins
are more strongly associated with the low MW BRAF complex, with
the differences being more pronounced in V600E cells than in WT-
expressing cells. This differential distribution could also be shown
by Western blot analyses of pooled high and low MW SEC fractions
(Fig 4I).
Taken together, BRAF localizes to structurally discrete macro-
molecular protein complexes. A considerable part of oncogenic
BRAFV600E resides in a complex of ~600 kDa together with CDC37
and HSP90. In contrast, the majority of BRAFWT is found in a
complex of ~200 kDa together with 14-3-3 proteins and MEK.
Pharmacological interference indicates differential regulation of
BRAFV600E- and BRAFWT-containing complexes
Several kinase inhibitors targeting BRAF itself or members of the
MAPK signaling cascade are currently in (pre-)clinical use. The so-
called paradoxical ERK activation observed in BRAFWT cells upon
treatment with BRAF inhibitors and in the context of excessive RAS-
GTP levels has highlighted the fact that a better understanding of
underlying protein dynamics is vital for the design of effective anti-
cancer therapies (Hatzivassiliou et al, 2010; Heidorn et al, 2010;
Poulikakos et al, 2010). Therefore, we tested the effects of the
approved drugs 17-AAG, a derivative of the HSP90/CDC37 complex
inhibitor geldanamycin, vemurafenib and trametinib, a MEK inhi-
bitor, on BRAFWT–protein and BRAFV600E–protein interactions. Anti-
HA affinity purifications from whole-cell lysate showed again the
differential binding of 14-3-3 proteins and CDC37 to the two variants
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Figure 4. Molecular composition of macromolecular BRAF complexes.
A Anti-HA affinity purification from whole-cell lysate of SILAC-labeled cells expressing WT and V600E is compared to unlabeled vector control cells (ctrl). BRAF is
marked in green, significantly interacting proteins in red (P < 0.05, BH corrected).
B A protein interaction network of BRAF binding partners identified in (A) is shown. Proteins interacting stronger with V600E are colored blue, proteins interacting
stronger with WT yellow. Proteins binding to both forms with similar strength are colored gray.
C, D CaCo-2tet SEC-PCP-SILAC profiles of differential BRAF binding partners are shown relative to the V600E profile.
E, F MEF SEC-PCP-SILAC profiles of differential BRAF binding partners are shown relative to the V600E profile (4-HT).
G, H (G) Anti-HA-BRAFV600E and (H) anti-HA-BRAFWT IPs from SEC fractions corresponding to high and low MW complexes indicate differential localizations of
interaction partners shown in (B). Relative protein abundances are based on iBAQ values.
I High and low MW complexes are separated by SEC, several SEC fractions were combined, and bulk protein abundance was analyzed by Western blot.
Source data are available online for this figure.
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of BRAF (Fig 5A and B). Whereas 17-AAG reduced CDC37-binding
to both BRAF forms, it did not influence BRAF/14-3-3 interactions.
Interestingly, 17-AAG also led to a reduction of the high molecular
weight complex containing BRAFV600E (Fig 5C) and reduced
BRAFV600E activity as indicated by MEK phosphorylation (Fig 5D
and E). Thus, the CDC37–BRAF interaction appears to be vital for
the formation of the large complex and for BRAFV600E activity.
Importantly, timing and concentration of 17-AAG were chosen in
such a way that BRAF levels were not yet affected by degradation
(Appendix Fig S5; Grbovic et al, 2006).
Vemurafenib had no obvious influence on the BRAFWT–CDC37
interaction; however, it did significantly decrease the BRAFV600E–
CDC37 interaction, also indicating that BRAFV600E signaling relies
on CDC37 (Grbovic et al, 2006). Furthermore, vemurafenib affected
the formation of the discrete large complex (Fig 5C) and decreased
BRAFV600E activity (Fig 5D and E). MEK, total as well as phosphory-
lated, interacted more strongly with BRAFWT compared to
BRAFV600E. Interestingly, MEK inhibition by trametinib reduced the
interaction of inactive MEK with BRAFWT and led to an increased
interaction with CDC37 in the case of both BRAFV600E and BRAFWT
(Fig 5A and B). As MEK inhibition abolishes the negative feedback
from ERK to BRAF (Brummer et al, 2003; Rushworth et al, 2006;
Pratilas et al, 2009; Ritt et al, 2010; Fritsche-Guenther et al, 2011),
these data could reflect an accumulation of active BRAF that needs
to be chaperoned by the HSP90/CDC37 complex.
BRAF high and low molecular weight complexes exhibit
differential activities
As the binding of CDC37 has been linked to BRAF activity (da Rocha
Dias et al, 2005; Grbovic et al, 2006) and as we could show that
vemurafenib and 17-AAG reduce the abundance of the high MW
complex, we analyzed BRAF kinase activities in SEC fractions of high
and low MW of BRAFV600E and BRAFWT by in vitro kinase assays
(Fig 6A and B). BRAFV600E in the high MW complex was 1.7 times
more active than BRAFV600E in the low MW complex. To further
prove that complex size was correlated with the active conformation
of BRAF, we purified endogenous BRAFWT from CaCo-2tet cells engi-
neered to express oncogenic KRASG12V upon Dox treatment (Mo¨ller
et al, 2014). Indeed, KRASG12V induced a segregation of initially
homogenous BRAF low MW population into high and low MW
complexes in CaCo-2tet cells (Fig 6C). Again, BRAFWT in the high
molecular weight complex was twice more active than BRAFWT in
the low molecular weight complex and kinase activity could be
blocked by the addition of vemurafenib (Fig 6B, Appendix Fig S6).
This reorganization of endogenous BRAFWT complexes and the asso-
ciated increase in activity was accompanied by the phosphorylation
of BRAFWT, as indicated by its electrophoretic mobility shift in SDS–
PAGE, and the phosphorylation levels of MEK and ERK (Fig 6D). As
expected from its property as a pan-RAF inhibitor (Wilhelm et al,
2004), sorafenib drastically reduced MEK and ERK phosphorylation
A
B
C D
E
Figure 5. Modulation of protein–protein interactions by pharmacological interference highlights differences betweenWT- and V600E-containing complexes.
A BRAF-containing protein complexes were purified via anti-HA IPs of WT- and V600E-expressing CaCo-2 cells treated with the indicated inhibitors. DMSO treatment
served as control.
B Quantification of blots shown in (A). Error bars indicate SD; *P < 0.05, **P < 0.01, unpaired Student’s t-test.
C, D The influence of 17-AAG and vemurafenib on (C) protein complexes of V600E-expressing CaCo-2 cells is analyzed by blue native PAGE and on (D) signal
transduction is analyzed by SDS–PAGE. The expression of V600E leads to the formation of two macromolecular complexes. Addition of both drugs leads to a
reduction in the larger protein complex and reduced BRAFV600E activity as indicated by the level of phospho-MEK (pMEK). Note: the antibodies used for detection of
MEK react less with phosphorylated MEK.
E Quantification of blots shown in (D). Error bars indicate SD; *P < 0.05, **P < 0.01, unpaired Student’s t-test.
Source data are available online for this figure.
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(Fig 6D). Interestingly and in stark contrast to BRAFV600E (Fig 5C),
abundance of the high MW complex of BRAFWT was further
increased by vemurafenib, while sorafenib shifted all detectable
BRAFWT molecules into the high MW fraction (Fig 6C). These effects
might reflect the different abilities of vemurafenib (or its predecessor
PLX4720) and sorafenib to induce weak and particularly stable BRAF
dimers, respectively (Ro¨ring et al, 2012).
To further confirm that distinct BRAF complexes can also be
observed endogenously and that these distinct complexes exhibit
differential activities, we turned again to the aforementioned MEF
BRAFfloxV600E/floxV600E system as well as to human melanoma cells.
Unlike to the situation of most human cancer cell lines, which co-
express BRAFWT and BRAFV600E and are likely to produce BRAF
complexes from three distinct homo-dimers consisting of either
wild-type and/or mutant proteins, our MEF isogenic experimental
setup produces only complexes made up by either wild-type or
mutant BRAF and therefore might provide a better discrimination of
the complexes in BN–PAGE. Indeed, 4-HT induces not only MEK
phosphorylation but also a shift of BRAF from the low to the high
MW fraction (Fig 6E and F), as it was already observed in CaCo-2tet
cells expressing HA-BRAFV600E (Fig 5C). Because both events are
vemurafenib sensitive, we conclude again that the high MW fraction
A
C
D
E
F H
G
B
Figure 6. BRAF complexes exhibit differential activities.
A The high and low molecular weight complexes of V600E are fractionated by SEC, and kinase activity is analyzed by in vitro kinase assays (IVKA). The
phosphorylation of purified GST-MEK is detected by a phosphosite-specific antibody recognizing phospho-Ser217/221 (pMEK). The HA signal is used as loading
control. Bar diagram shows quantification of blots normalized to HA-BRAF. AU: arbitrary unit. Error bars indicate SD; *P < 0.05, unpaired Student’s t-test.
B IVKA of WT complexes. Error bars indicate SD; *P < 0.05, unpaired Student's t-test.
C, D WT complexes are analyzed by (C) BN–PAGE and (D) SDS–PAGE followed by Western blot using CaCo-2 cells inducibly expressing KRASG12V.
E, F MEFs BRAFfloxV600E/floxV600E expressing WT or V600E upon 4-HT induction are analyzed as in (C and D). EtOH treatment served as vehicle control.
G, H Human SBcl2 melanoma cells expressing endogenous NRASQ61K are treated and analyzed as described in panels (C and D).
Source data are available online for this figure.
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is dependent on either the activity or active conformation of
BRAFV600E. Finally, we used human SBcl2 melanoma cells, which
lack a BRAF mutation, but carry an endogenous NRASQ61K oncogene
and in which paradoxical ERK activation can be rapidly provoked
by BRAF selective inhibitors in a dimerization-dependent manner
(Fig 6G and H; Ro¨ring et al, 2012). Like in KRASG12V-expressing
CaCo-2tet cells, vemurafenib and sorafenib promoted or completely
induced the transfer of BRAFWT from the low into the high MW
complex, respectively (Fig 6G). In summary, our data indicate that
BRAF activation leads to the assembly of distinct protein complexes
that exhibit differential activities and may address specific roles
within the cell.
Discussion
BRAF is a therapeutic target of growing relevance across various
clinical disciplines (Turski et al, 2016). Despite all the impressive
therapeutic responses elicited by BRAF inhibitors reported since
2010, these drugs often fail to provide sustainable treatment options
due to the emergence of drug resistance and side effects associated
with the aforementioned “paradoxical ERK activation” observed in
cells with elevated RAS activity (Samatar & Poulikakos, 2014;
Yaktapour et al, 2014; Lavoie & Therrien, 2015). Indeed, this
phenomenon illustrates that the complexity of RAF signaling has
been underestimated and highlights the need for a better under-
standing how BRAF entertains protein–protein interactions, forms
protein complexes, and how these events guide the kinase through
its activation cycle.
With the current study, we aimed to decipher the complexities of
signaling complexes organized by either wild-type or oncogenic
BRAF by applying a recently developed proteomic approach to a
panel of human and murine cell line models and primary cells. By
fitting CaCo-2tet cells with inducible BRAFWT, BRAFV600E, and
KRASG12V expression systems, we could study the molecular func-
tions of respective oncoproteins in an isogenic setting. Ectopic BRAF
expression did not alter global protein abundances, and the
observed ninefold increase in BRAF itself is still in the range of
abundance levels observed in patients harboring acquired resistance
to BRAFV600E inhibition by gene ultra-amplification (Moriceau et al,
2015). Importantly, not only do we corroborate our previous finding
from BN–PAGE analyses that BRAFWT and BRAFV600E predominantly
localize to protein complexes of distinct and discrete sizes (Ro¨ring
et al, 2012), but we also demonstrate now that these complexes differ
in their composition and activity. We show that the formation of the
larger BRAF complexes represents a function of kinase activation as
BRAFWT is transferred into the larger complex upon inducible
expression of oncogenic KRAS (Fig 7). Importantly, our key findings
were confirmed in the human melanoma cell line SBcl2 and an
isogenic MEF system expressing endogenous BRAFWT and BRAFV600E,
indicating that our results are neither cell line nor organism depen-
dent nor influenced by BRAF expression levels. However, as we did
not perform detailed interactome studies of the different complexes in
all tested cell lines–drugs combinations, we cannot rule out that the
similar sized complexes differ in single components. This has to be
addressed by future studies.
It is well understood that BRAFWT and some of its gain-of-
function mutants need to form side-to-side homo- and heterodimers
(Rajakulendran et al, 2009; Thevakumaran et al, 2015), while
BRAFV600E can potentially signal as a monomer, for example, by
introduction of mutations abolishing DIF function and/or 14-3-3
binding (Poulikakos et al, 2011; Ro¨ring et al, 2012; Freeman et al,
2013). However, this does not necessarily mean that BRAFV600E
always exists as a monomer in living cells. In fact, we and others
have shown that BRAFV600E and other high activity oncoproteins are
more abundantly purified in their dimeric form than BRAFWT
Figure 7. Model of BRAF complex dynamics.
Left cartoon: BRAFWT is present in a monomeric form and depending on its phosphorylation status (S365, S729 marked in red) bound to 14-3-3. In the presence of active
RAS, BRAF becomes phosphorylated and forms homo- or heterodimers by conformational changes in the kinase domain (Thevakumaran et al, 2015) and the concerted
action of 14-3-3 proteins promoting dimerization at the RAF C-termini. Dimerization promotes allosteric activation and a fully active conformation of BRAF, leading to
recruitment of one asymmetric HSP90/CDC37 dimer per RAF protomer. Right cartoon: In contrast to BRAFWT, BRAFV600E is locked in an active conformation (Wan et al,
2004; Thevakumaran et al, 2015) and thus can remain active upon mutation of dimerization devices such as the C-terminal 14-3-3 motif and the DIF (Röring et al, 2012).
However, in cancer cells, BRAFV600E is predominantly found in a dimeric state. Upon translocation to the high molecular weight complexes BRAF variants become
dephosphorylated reducing the interaction with 14-3-3 proteins and concurrently increasing the interaction with HSP90/CDC37. See Discussion for further details and
additional references.
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(Ro¨ring et al, 2012; Thevakumaran et al, 2015). Using BN–PAGE,
we could show that both ectopically and endogenously expressed
BRAFV600E appear more likely in larger protein complexes than
BRAFWT and that the HMW complex requires an intact DIF in BRAF,
suggesting that dimerization represents a key prerequisite for its
formation (Ro¨ring et al, 2012). More importantly, we have identified
now at least two distinct multimeric, macromolecular protein
complexes harboring BRAF. One complex of ~600 kDa is character-
ized by BRAF, CDC37, HSP90, and FKBP5, and the other predomi-
nant complex of ~200 kDa contains BRAF, 14-3-3 proteins, MEK,
and PPP2R2A (Fig 7).
Although some of the complex components such as HSP90/
CDC37 and the 14-3-3s have been identified as BRAF interactors
previously (Jaiswal et al, 1996; Papin et al, 1996; Eisenhardt et al,
2016), we report here for the first time their differential binding
pattern. Binding of 14-3-3 proteins is critical for BRAF complex
distribution as mutations of their recruitment sites altered the ratio
between the large and small BRAF complexes. In addition to these
well-established interaction partners, our SEC-PCP-SILAC approach
also identified the discrete distribution of less known interaction
partners, such as FKBP5 that we recently identified as BRAF interac-
tion partner in chicken DT40 and human MCF-10A cells (Eisenhardt
et al, 2016). Here, we show that this peptidyl-prolyl cis/trans
isomerase represents a hallmark of the high molecular weight BRAF
complex. FKBP5 plays a role in the regulation of multiple signaling
pathways, in tumorigenesis and chemoresistance (Li et al, 2011),
and has been identified to act as a negative regulator of AKT (Pei
et al, 2009). AKT3 lowers BRAFV600E activity by phosphorylating
BRAF within the 14-3-3 binding motif around Ser365 that is critical
for BRAF inhibition, even within the highly active V600E context
(Cheung et al, 2008). As FKBP5 interacts with BRAFV600E in the
high MW complex in which phosphorylation of BRAF at Ser365 is
almost absent, it is tempting to speculate that the FKBP5-mediated
inactivation of AKT3 accounts for the loss of pS365 on BRAF and
thereby the reduction of 14-3-3 in the high MW complex. FKBP5
was absent in the low MW complex in which Ser365 was phospho-
rylated. On the other hand, PPP2R2A interacts with BRAFV600E in
the low MW complex and has been suggested to dephosphorylate
hyper-phosphorylated BRAF (Ritt et al, 2010), suggesting that
BRAFV600E in this complex is less active or becomes inactivated.
Alternatively but not necessarily excluding these possibilities, loss
of 14-3-3 in the high MW BRAFV600E complexes could expose pS365
and pS729 to phosphatases, thereby preventing 14-3-3 re-binding
by dephosphorylation.
The reciprocal distribution of the HSP90/CDC37 complex and the
14-3-3 isoforms is a surprising finding (Fig 7). In fact, one of the
first studies reporting the BRAF/HSP90 interaction in unstimulated
and NGF-treated PC12 cells suggested a more or less constitutive
interaction between BRAFWT and the chaperone complex (Jaiswal
et al, 1996). Likewise, despite the dynamic on/off recruitment of
14-3-3s to the N-terminal 14-3-3 binding site (S365 in BRAF) during
the activation cycle of BRAF and CRAF (Dhillon et al, 2002;
Rodriguez-Viciana et al, 2006), it was assumed that the 14-3-3 dimer
remains more or less constitutively bound to the high affinity 14-3-3
binding motif at the C-terminus of RAF-kinases (Ser729 in BRAF),
including BRAFV600E. This assumption was based on co-immunopre-
cipitation studies and GST-14-3-3 pulldowns and by genetic data
showing that this protein–protein interaction appears necessary for
auto-inhibition, dimerization, and MEK phosphorylation (MacNicol
et al, 2000; Brummer et al, 2006; Fischer et al, 2009; Ritt et al,
2010). Nevertheless, it must be kept in mind that neither co-
immunoprecipitation/pull-down studies nor genetic approaches can
provide the spatial resolution delivered by SEC-PCP-SILAC. In hind-
sight, however, our discovery that BRAFV600E occurs in at least two
complexes, with the larger being more active and bound to HSP90/
CDC37 but basically lacking 14-3-3 proteins, provides now a mecha-
nistic explanation for several phenomena published within the last
decade. Firstly, we and others have shown that loss of 14-3-3 bind-
ing to Ser729 abrogates the signaling potential of BRAFWT and
several gain-of-function mutants but not of BRAFV600E (Brummer
et al, 2006; Fischer et al, 2009; Ritt et al, 2010). Thus, BRAFV600E,
despite the fact that it can bind to 14-3-3s if it is present in the low
MW complex, does not require these phospho-serine binding
proteins for downstream signaling, hence there is no need to retain
them in the large and more active complex. Secondly, while the
interaction of 14-3-3 proteins with the C-terminus of BRAF is critical
to initiate dimerization (Ritt et al, 2010), a considerable fraction of
the low MW 14-3-3-containing complex could represent a popula-
tion that has been inactivated recently. Indeed, AMPK-mediated
phosphorylation of Ser729 has been suggested to disrupt the BRAF/
KSR1 complex and thereby to attenuate downstream signaling (Shen
et al, 2013). Thirdly, BRAFV600E associates more strongly with the
HSP90/CDC37 complex compared to BRAFWT (Grbovic et al, 2006).
Fourthly and most critically from a clinical perspective, our data
explain as to why HSP90 inhibitors such as geldanamycin or ganete-
spib show efficacy in BRAF mutant tumor cells, even in those with
acquired vemurafenib resistance, while sparing cell lines lacking
BRAFV600E mutations (da Rocha Dias et al, 2005; Grbovic et al,
2006; Acquaviva et al, 2014). Thus, the more active high MW
complex of BRAFV600E might represent the major oncogenic driver
and consequently its tight interaction with HSP90/CDC37 provides
an Achilles heel to BRAFV600E addiction of tumor cells by HSP90
inhibitors.
But what determines whether a BRAF molecule becomes incor-
porated into the low or high MW complex? Based on our data and
previous work, we posit that it is the combination of the active
conformation of the kinase domain and the dimerization status of
BRAF that determines the composition, order and quaternary struc-
ture of these complexes. Indeed, DIF mutations impair not only the
homo-dimerization of BRAFV600E, but also its incorporation into the
high MW complex (Ro¨ring et al, 2012). Moreover, by assessing
endogenous BRAFWT in CaCo-2tet cells in the absence or presence
of KRASG12V, we now demonstrate that this oncogenic GTPase not
only activates BRAF/MEK/ERK signaling, as expected, but also
shifts BRAF from the low into the high MW complex. As active RAS
promotes dimerization of RAF, most likely by promoting the afore-
mentioned conformational change within its kinase domain ulti-
mately leading to DIF exposure (Heidorn et al, 2010; Thevakumaran
et al, 2015; Ko¨hler et al, 2016), this observation implies again that
BRAF has to acquire a fully active conformation to assemble the
high MW complex (Fig 7). Our observation that vemurafenib
disrupts the high MW complexes organized by HA-tagged or
endogenous BRAFV600E further supports this model. Moreover,
Thevakumaran et al (2015) demonstrated that this inhibitor induces
an “off-state like” conformation and thereby acts as a homo-dimer
breaker. Thus, based on these insights, it is not surprising that DIF
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mutations or vemurafenib abolish the high MW complex. Likewise,
vemurafenib, which has been shown to disrupt the interaction
between CDC37 and the isolated kinase domain of BRAF (Polier
et al, 2013), also reduced the abundance of complexes between
CDC37 and full-length BRAFV600E in our experimental system. This
was associated with a reduction in kinase activity and the abun-
dance of the high MW complex. In summary, our data suggest that
BRAFWT, once it has acquired its fully active conformation, or
BRAFV600E, which is stabilized in its active conformation due to a
mutation-specific salt-bridge (Wan et al, 2004; Hu et al, 2013;
Thevakumaran et al, 2015), display a higher affinity to but also
dependence for the HSP90/CDC37 complex (Fig 7). This concept is
further supported by the BRAFS365A mutant, which is predominantly
incorporated into the large BRAF complex. This mutant is primed
for full activation by relief from 14-3-3-mediated auto-inhibition
(MacNicol et al, 2000; Brummer et al, 2006; Fischer et al, 2009; Ritt
et al, 2010), probably leading to a better exposure of the kinase
domain and facilitating dimerization-driven transactivation (Ro¨ring
et al, 2012). Thus, this mutant imitates a state in which BRAFWT
only exists following its recruitment by RAS-GTP. This concept is
supported by previous studies showing that RAS-GTP activates
BRAF and CRAF by cooperating with a phosphatase complex
that displaces 14-3-3 proteins and prevents their re-binding by de-
phosphorylation of S365 (or S259 in CRAF) (Dhillon et al, 2002;
Rodriguez-Viciana et al, 2006; Deswal et al, 2013).
We also investigated higher order complexes of BRAFWT in the
setting of the paradoxical action of vemurafenib in NRASQ61K-driven
human melanoma cells and in the context of the pan-RAF inhibitor
sorafenib. Interestingly, these experimental setups revealed the
formation of larger complexes, although ERK phosphorylation was
further reduced by sorafenib. At first glance, this finding appears to
contradict our model, which is in part based on the vemurafenib-
sensitive high MW BRAFV600E complexes. However, if we consider
that sorafenib and, albeit to a lesser extent, also vemurafenib do not
abrogate, but rather promote BRAF hetero-dimerization (Heidorn
et al, 2010; Ro¨ring et al, 2012), it is conceivable that these high MW
complexes differ in their composition from those organized by
BRAFV600E and might rather contain RAF heterodimers at their
center. This represents an area for future studies.
Our data have several important translational implications.
Firstly, it is critical to comprehensively study BRAF isoform-specific
protein–protein interactions in an inhibitor-dependent fashion as
each drug might provoke distinct multi-protein complexes.
Secondly, the clinically relevant MEK inhibitor trametinib, which
reduces the negative feedback from ERK to BRAF (Brummer et al,
2003; Rushworth et al, 2006), enforces CDC37 association and
thereby probably sustains the longevity of the large and more active
complexes. This might be relevant for our understanding of MEK
inhibitors, for example, within a combination therapy setting.
Thirdly, next to directly targeting BRAF activity by ATP competitors,
compounds blocking the HSP90/CDC37 interaction could provide
an additive value, in particular as HSP90 inhibitors are increasingly
trialed and applied in a clinical setting (Neckers & Workman, 2012;
Acquaviva et al, 2014). Indeed, a very recent report demonstrated
that the HSP90 inhibitor XL888 suppressed vemurafenib induced
paradoxical ERK activation in NRAS mutant melanoma cell lines
and the incidence of secondary skin lesions in vemurafenib-treated
patients (Phadke et al, 2015). Taken together, the presented work
sheds new light on the BRAF activation cycle and the quaternary
structure of multimeric, cytosolic BRAF complexes. It underscores
the importance of studying the spatial organization of multi-protein
complexes and identifies important regulatory mechanisms, which
can be employed in the design of new combination therapies
addressing hyperactive BRAF in disease.
Materials and Methods
Cell lines
Plat-E, SBcl2, CaCo-2tet HA-BRAFWT, CaCo-2tet HA-BRAFV600E,
CaCo-2tet KRASG12V, and CaCo-2tet vector cells were cultivated as
previously described (Ro¨ring et al, 2012; Herr et al, 2015). Expres-
sion of HA-BRAFWT, HA-BRAFV600E, or KRASG12V was induced with
2 lg/ml doxycycline (Sigma-Aldrich, Taufenkirchen, Germany) for
indicated time points or if not mentioned differently for 48 h. All
cell lines were cultivated under water vapor-saturated conditions at
37°C and 5% CO2. Inhibitors were dissolved in DMSO and final
concentrations were: vemurafenib 1 lM, 17-AAG 1 lM, trametinib
10 nM; maximum concentration of DMSO was 0.01%.
Mouse embryonic fibroblasts
The generation of the MEF BraffloxV600E/floxV600E and MEF
BraffloxV600E/floxV600E/Rosa26::CreERT2 was performed as follows.
All procedures involving mice were carried out in accordance
with the local animal ethics committee (X-14/47H). Conditional
BraffloxV600E/knock-in mice were originally generated by the
McMahon laboratory and were described in detail previously
(Dankort et al, 2007). Mice were purchased from The Jackson Labo-
ratory in Bar Harbor (Maine, USA) and delivered on a pure C57BL/6
background. Genotyping was performed using the protocols
published by Dankort et al (2007). After embryo transfer into our
facility, mice were maintained on a C57BL/6 background and then
mated with Rosa26::CreERT2 mice (Ventura et al, 2007), also
backcrossed to a C57BL/6 background. Subsequently, the resulting
BraffloxV600E/+/Rosa26::CreERT2F1 animals were bred to homozy-
gosity in respect to the BraffloxV600E allele. BraffloxV600E/floxV600E/
Rosa26::CreERT2 animals were then mated with BraffloxV600E/floxV600E
mice to generate embryos for MEF preparation as described previ-
ously (Ro¨ring et al, 2012). Briefly, embryos were isolated at embry-
onic day 12.5. The head and fetal liver were removed, and the
torso was minced and digested in 0.25% trypsin/EDTA solution at
37°C for 30 min. Cells were spun down and then cultivated in
Dulbecco’s modified Eagle’s medium supplemented with 20% fetal
calf serum, 2 mM L-glutamine, 10 mM HEPES, 200 U/ml penicillin,
200 lg/ml streptomycin; 2.5 lg/ml amphotericin B all from PAN,
Aidenbach, Germany) in a vapor-saturated atmosphere at 37°C and
5% CO2. MEF pools with the appropriate genotypes were expanded
for a few days and then immortalized by infection using the
pQCXIH/Tag retroviral construct, which encodes the large T anti-
gen (Tag) of simian virus 40. Infected cells were selected with
hygromycin B (200 lg/ml). Immortalized MEFs, which retained
their normal morphology and displayed proper contact inhibition
response upon confluency, were used for further studies. Expres-
sion of BrafV600E was induced with a 1 day 1 lM 4-hydroxytamoxifen
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(4-HT; Sigma-Aldrich, Taufenkirchen, Germany) pulse to allow for
CreERT2-mediated recombination of BraffloxV600E alleles.
Stable isotope labeling by amino acids in cell culture (SILAC)
For SILAC labeling, CaCo-2tet HA-BRAFWT, CaCo-2tet HA-
BRAFV600E, and CaCo-2tet vector cells were grown in high glucose
(4.5 g/l) SILAC-DMEM (PAN, Aidenbach, Germany) with 1% gluta-
mine, 1% penicillin/streptomycin, and 10% dialyzed fetal bovine
serum (Invitrogen, Darmstadt, Germany) containing either 88.3 mg/ml
L-arginine HCl, 76.3 mg/ml L-lysine for light labeling (Arg0, Lys0)
(Sigma-Aldrich), or L-arginine-13C6
14N4 and L-lysine-
2H4 (Arg6,
Lys4) for medium-heavy labeling, or L-arginine-13C6
15N4 and L-lysi-
ne-13C6
15N2 (Arg10, Lys8) for heavy labeling (Eurisotop,
Saarbru¨cken, Germany). The cells were grown for at least 2 weeks
to ensure 100% incorporation of labeled amino acids.
Western blot
To gain whole-cell lysate (WCL) from cells, these were lysed in
either normal lysis buffers (NLB: 50 mM Tris/HCl, pH 7.5; 1%
Triton X-100; 137 mM sodium chloride; 1% glycerin; protease inhi-
bitors and phosphatase inhibitors) or 4% SDS in 100 mM Tris, pH
7.6 (for inhibitor titration Western blots). Protein concentration
determination was performed via BCA assay (Thermo Fisher Scien-
tific, Langenselbold, Germany). Equal protein amounts were loaded
for PAGE. Blotted proteins were visualized with horseradish peroxi-
dase-conjugated secondary antibodies (Roche Diagnostics GmbH,
Mannheim, Germany) using the Blot Detection Kit Immobilon
Western (Millipore, Schwalbach, Germany) and the LAS-4000
reader (Fujifilm Europe GmbH, Du¨sseldorf, Germany). Densitometry
measurements were performed using ImageJ 1.49k (Wayne
Rasband, National Institutes of Health, USA).
Immunoprecipitations
Cells were lysed in NLB as described for Western blot. Depending
on the subsequent analysis strategy the volume of anti-HA (3F10)
affinity matrix (Roche Diagnostics GmbH, Mannheim, Germany) to
precipitate HA-BRAF was chosen to match 30–60 lg of anti-HA
antibody. For immunoprecipitation of CDC37, 15 lg of anti CDC37-
antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany) was
used. The same amount of normal mouse IgG (Santa Cruz Biotech-
nology Inc., Heidelberg, Germany) served as control for potential
unspecific protein binding. Protein G sepharose fast flow beads
(Sigma-Aldrich, Taufenkirchen, Germany) were mixed thoroughly
before the same volume as antibody solution was taken to a fresh
reaction tube. The antibody solution was then added on top. Last,
the sample lysate was added into the same reaction tube. An
aliquot of each lysate was retained before IP serving as an input
control for the presence of the protein being precipitated. IPs were
incubated at 4°C on an overhead rotator overnight. The next day
an aliquot of the supernatant was taken apart as flow through
(FT) control. The pelleted beads were subsequently washed three
times with lysis buffer and resuspended in 2× SDS loading buffer
with 5 mM DTT. Precipitated proteins were eluted by boiling at
95°C. Equal volumes of eluates were loaded for analysis via
Western blot.
Antibodies
Antibodies used in this study are from Cell Signaling Technology, MA,
USA: anti-phospho-MEK1/2 (pS217/221) (# 9121L), anti-MEK1/2
(# 9122L), anti-phospho-p44/42 MAPK (ERK1/2) (Thr202/Tyr204)
(#9101), anti-p44/42 MAPK (ERK1/2) (#9102); from Santa Cruz
Biotechnology Inc., Heidelberg, Germany: anti-Ras (# 3965), anti-
GAPDH (FL335) (# sc-25778), anti-BRAF (F7) (# sc-5284), anti-CDC37
(C-11) (# sc-13129), anti-pan-14-3-3 (H-8) (# sc-1657), normal mouse
IgG (sc-2025); anti-HA (3F10) (# 11867423001, Roche Diagnostics
GmbH, Mannheim, Germany), anti-HA (3F10) Affinity Matrix
(# 11815016001, Roche); donkey anti-rabbit HRP (# NA9344V, GE
Healthcare, Munich, Germany), sheep anti-mouse HRP (# NA931V, GE
Healthcare); goat anti-rat HRP (# 112-035-003, Dianova GmbH,
Hamburg, Germany); anti-mouse IgG VeriBlot for IP secondary anti-
body (HRP) (# ab131368, Abcam, Cambridge, United Kingdom). The
anti-BRAFV600E (VE1) was kindly provided by Prof. A. v. Deimling and
has been described previously (Capper et al, 2011; Ro¨ring et al, 2012).
BN–PAGE analysis
CaCo-2 cells were plated 24 h before doxycycline-induced expres-
sion of HA-BRAFV600E or KRASG12V. Subsequent cells were either
treated for 1 h with 1 lM PLX4032 (vemurafenib; Selleck Chemi-
cals, Munich, Germany) or with 10 lM sorafenib (Santa Cruz
Biotechnologies, USA) or for 4 h with 1 lM 17-AAG (Tanespimycin;
Selleck Chemicals, Munich, Germany). DMSO (Sigma-Aldrich,
Taufenkirchen, Germany) served as negative control.
Alternatively, SBcl2 melanoma cells were plated 24 h prior to
treatment with PLX4032, sorafenib, or DMSO in the same manner as
described for CaCo-2 cells. Cells were lysed by adding 1 ml of cold
BN-lysis buffer (20 mM Bis-Tris, pH 7.0, 20 mM NaCl, 2 mM EDTA,
pH 8.0, 10% glycerol) supplemented with 1% Triton X-100,
protease, and phosphatase inhibitors (Complete protease inhibitor
cocktail, PhosSTOP EasyPack; Roche Diagnostics GmbH, Mannheim,
Germany) to the cell culture dish. After incubation on a rocking plat-
form for 30 min at 4°C, the lysate was centrifuged at 13,000 g at 4°C
for 10 min. The supernatant was removed and stored on ice for the
following steps. A 1:20 dilution of a ferritin mark (440 and 880 kDa;
Sigma-Aldrich, Taufenkirchen, Germany) was used as marker. 2 ll
of sample was loaded on a precast BN gel (NativePAGETM Novex
4–16% Bis-Tris Protein Gels; Invitrogen, Darmstadt, Germany)
and overlaid with dark blue cathode buffer (NativePAGE Running
buffer kit; Invitrogen, Darmstadt, Germany). 1% glycerol was
added to the samples before loading. The BN gel electrophoresis
was performed at 4°C for 1 h using dark blue cathode buffer
and anode buffer (NativePAGETM Running buffer kit; Invitrogen,
Darmstadt, Germany), followed by two more hours with light
blue cathode buffer and anode buffer (NativePAGETM Running
buffer kit; Invitrogen Darmstadt, Germany).
Subsequently, BN–PAGE separated proteins were blotted onto
PVDF membranes (Immobilon-PSQ; Merck Millipore, Merck KGaA,
Darmstadt, Germany) by wet protein transfer using 1× TGS contain-
ing 0.02% SDS (Bio-Rad, Munich, Germany) and 20% methanol
(VWR, International GmbH, Bruchsal, Germany). Loading controls
of BN–PAGE experiments were made from cell lysates gained from
BN–PAGE cell lysis as described above. Equal volumes of each
sample were loaded for analysis via Western blot.
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In vitro kinase assay (IVKA)
Expression of HA-BRAFV600E or KRASG12V in CaCo-2tet cells was
induced, and size exclusion chromatography (SEC) was performed.
SEC fractions corresponding to the high molecular weight complex
(fractions 23–29) and fractions corresponding to the low molecular
weight complex (fractions 38–46) were combined after chromato-
graphic separation. From BRAFV600E samples, 1, 3, 5, and 10 ll
were supplemented with kinase assay buffer (KAB; 20 mM
4-morpholinepropanesulfonic acid (MOPS), pH 7.2; 5 mM EGTA,
1× phosphatase inhibitors, 1 mM dithiothreitol) to 20 ll total
volume. Then, these suspensions were mixed with 2 lg recombinant
GST-MEK1 and 5 mM ATP in 20 ll KAB. The IVK reaction was incu-
bated at 30°C for 30 min at 700 rpm in a thermomixer. For the IVKA
performed with BRAFWT from CaCo-2tet KRASG12V cells, the volume
of the combined fractions was decreased to half by using a 10 kDa
cutoff filter (Sartorius AG, Go¨ttingen, Germany). Then, 10 and 20 ll
were supplemented with SEC lysis buffer to 40 ll total volume.
Additionally, 40 ll of the concentrated, combined SEC fractions were
left unsupplemented. Next, these suspensions were mixed with 40 ll
of KAB. Finally, 80 ll of the GST-ATP-MEK-Mix was added. IVK
reaction was incubated at 30°C as well but for 60 min. Kinase
reactions were immediately stopped by addition of 2× SDS sample
buffer containing 1 mM DTT and boiling for 10 min at 95°C. Subse-
quently, the reactions were analyzed by Western blot. Here, the
degree of phosphorylated GST-MEK served as read out for the kinase
activity. Detection against BRAF or HA served as loading control.
SEC-PCP-SILAC
After doxycycline treatment, cells were washed once with ice-cold
DPBS (PAN, Aidenbach, Germany) and subsequently lysed in a
Dounce homogenizer (Wheaton, Millville, NJ USA) in size exclusion
chromatography (SEC) mobile phase (50 mM KCl, 50 mM
NaCH3COO, pH 7.2) including protease inhibitors and phosphatase
inhibitors (Roche Diagnostics GmbH, Mannheim, Germany) (SEC
lysis buffer). 1.5 ml of each lysate was clarified of debris by a
10-min centrifugation (3,220 g). Soluble, cytosolic complexes were
enriched by a 20-min ultracentrifugation (100,000 g) using a
iodixanol (Sigma-Aldrich, Taufenkirchen, Germany) gradient before
being concentrated to 100 ll using ultrafiltration (100,000 MWCO;
Sartorius AG, Go¨ttingen, Germany). Cytosolic complexes were
loaded onto an A¨KTA Purifier 10 semi-preparative HPLC (GE
Healthcare, Munich, Germany) equipped with a 600 × 7.8 mm
BioSep4000 Column (Phenomenex, Aschaffenburg, Germany)
(resolving power 25,000 plates) controlled at 15°C and a flow rate of
0.5 ml/min. 20 fractions were collected from 20 to 30 min, and 34
fractions were collected from 30 to 41.5 min. The corresponding
medium and heavy fractions were recombined just after size
exclusion chromatographic separation. The light SILAC popula-
tions were similarly separated by SEC, after which all fractions
were recombined and mixed thoroughly before being spiked
equally into each of the medium/heavy fractions.
MS sample preparation
Fractions from SEC-PCP-SILAC were conducted to an in-solution
digest. For protein denaturation and reduction, 1% sodium
deoxycholate and 10 mM DTT were added to each fraction prior to
boiling at 95°C for 5 min followed by 56°C for 20 min. To alkylate
proteins, addition of 4.5 mM iodoacetamide and incubation at room
temperature for 25 min in the dark followed. A tryptic digest was
performed overnight at 37°C. The next day, the peptides were puri-
fied via STAGE tip (Rappsilber et al, 2007).
For in-gel digestion, protein mixtures were separated by SDS–
PAGE using 4–12% Bis–Tris mini gradient gels (NuPAGE, Invitro-
gen, Darmstadt, Germany). The gel lanes were cut into 10 equal
slices, which were in-gel digested with trypsin (Promega,
Mannheim, Germany) (Shevchenko et al, 2006), and the resulting
peptide mixtures were processed on STAGE tips. The effect of
oncogene overexpression on global protein abundance was
measured from WCL of SILAC-labeled CaCo-2tet cells that were
lysed in 4% SDS in 100 mM Tris pH 7.6. Lysates were denatured
and reduced at 95°C with 1 mM DTT followed by alkylation with
5.5 mM iodoacetamide at room temperature in the dark. Samples
were conducted to an in-gel digest as described above. For MS
analysis of BRAF interaction partners, an anti-HA IP was performed
as described above with WCL of SILAC-labeled CaCo-2tet cells.
Eluted proteins were alkylated and processed as described above to
in-gel digest.
MS analysis
Mass spectrometric measurements were performed on LTQ Orbi-
trap XL mass spectrometer (Thermo Fisher Scientific, Langensel-
bold, Germany) coupled to an Agilent 1200 nanoflow–HPLC
(Agilent Technologies GmbH, Waldbronn, Germany) or a NanoLC
Ultra (Eksigent, AB Sciex, Radio Rd Redwood City, CA, USA).
HPLC-column tips (fused silica) with 75 lm inner diameter (New
Objective, Woburn, MA, USA) were self-packed (Ishihama et al,
2002) with Reprosil–Pur 120 ODS–3 (Dr. Maisch, Ammerbuch,
Germany) to a length of 20 cm. Samples were applied directly
onto the column without pre-column. A gradient of A (0.5%
acetic acid (high purity, LGC Promochem, Wesel, Germany) in
water and B (0.5% acetic acid in 80% ACN (LC–MS grade, Wako
Chemicals GmbH, Neuss, Germany) in water) with increasing
organic proportion was used for peptide separation (loading of
sample with 2% B; separation ramp: from 10 to 30% B within
80 min). The flow rate was 250 nl/min and for sample applica-
tion 500 nl/min. The mass spectrometer was operated in the
data-dependent mode and switched automatically between MS
(max. of 1 × 106 ions) and MS/MS. Each MS scan was followed
by a maximum of five MS/MS scans in the linear ion trap using
normalized collision energy of 35% and a target value of 5,000.
Parent ions with a charge state from z = 1 and unassigned charge
states were excluded for fragmentation. The mass range for MS
was 370–2,000 m/z. The resolution was set to 60,000. MS param-
eters were as follows: spray voltage 2.3 kV; no sheath and auxil-
iary gas flow; ion transfer tube temperature 125°C.
Identification of proteins and protein ratio assignment
using MaxQuant
The MS raw data files were uploaded into the MaxQuant software
(Cox & Mann, 2008) version 1.3.0.5., which performs peak detection,
label-free quantification, and generates peak lists of mass error
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corrected peptides using the following parameters: Carbamido-
methylcysteine was set as fixed modification, and methionine oxida-
tion and protein amino-terminal acetylation were set as variable
modifications. Three miss cleavages were allowed, enzyme speci-
ficity was trypsin/P + DP, and the MS/MS tolerance was set to
0.5 Da. Peak lists were searched by Andromeda for peptide identifi-
cation using a Uniprot human database from July 2012 containing
common contaminants such as keratins and enzymes used for in-gel
digestion (86,749 entries). Peptide lists were further used by
MaxQuant to identify and relatively quantify proteins using the
following parameters: peptide and protein false discovery rates were
set to 0.01, maximum peptide posterior error probability (PEP) was
set to 1, minimum peptide length was set to 7, the PEP was based on
Andromeda score, minimum number peptide for identification and
quantitation of proteins was set to one and must be unique, and
identified proteins have been re-quantified.
The mass spectrometry proteomics data have been deposited to
the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identifier PXD004585 (Vizcaino et al, 2016).
Analysis of SEC-MS data
Preprocessing
From the LC-MS/MS runs of the individual size exclusion fractions,
we extracted the SILAC ratios of the signal of each protein in each
fraction compared to the spiked in standard. Combining the ratios
across the size exclusion fractions, we could construct
chromatograms. Since we observed some differences in the
chromatography between the replicates, we processed the data from
the replicates separately.
The extracted chromatograms contained low level noise which
could potentially interfere with downstream analysis steps, and
thus, when plotting the distribution of all ratios, we observed a
bimodal distribution. Based on the assumptions that the lower
of the two underlying distributions contained the noise, we fitted
two Gaussian distributions to the frequency of SILAC ratios
(Appendix Fig S2A). The two distributions were partially overlap-
ping, and thus, we selected as noise threshold the point in which
the signal from the noise was 10 times more frequent than the signal
from the useful data. We selected this threshold to ensure that we
would only remove few data points from actual elution profiles (fil-
ter 1). Conversely, to ensure that we observed a sufficiently strong
signal to confidently assign interactions, we required at least one
ratio above the point where the true data signal is 10-fold more
frequent than the noise (filter 2). For some proteins, especially
those close to the detection limit, the chromatogram appeared
scratchy with unexpected peak shapes. To ensure that only
proteins which showed a reasonable peak shape were kept, we
required a signal in at least five consecutive fractions. In cases
where only data for four points were available, the fifth was
imputed as the average of the value in the two neighboring
fractions. The first two filter steps removed only few protein IDs
from the dataset, but the number of ratios for each protein was
considerably lower due to the removal of noise (Appendix Fig S2B
and C). However, the requirement of signal being present in five
consecutive fractions caused a ~1/3 reduction in the number of
proteins. In Dataset EV1 are the filtered elution profiles from both
samples (V600E and WT) in the three replicates.
Interaction inference
To infer potentially interacting proteins from the collection of chro-
matograms, we screened the data for proteins with highly similar
elution patterns. In the case a protein is part of two or more
complexes, it would have several elution peaks, while the potential
interactors might overlap with only one of these (Appendix Fig
S2D). To be able to catch respective interactions, we fitted between
1 and 3 Gaussian distribution to raw chromatograms, with each fit-
ted distribution corresponding to different putative interactions.
Since not all chromatograms could be decomposed into a mixture of
Gaussian distributions, we filtered out proteins in which the residu-
als between the data and the fit were above the 1.58 interquartile
ranges (corresponding to the whiskers on a standard boxplot). In
the majority of cases (91%), we fitted only one Gaussian, with the
proteins remaining split between fitting two and three Gaussians for
7 and 2% of proteins, respectively.
To score the degree of co-elution, we calculated the distance
between each Gaussian curve to all other Gaussian fits. To estimate
a suitable cutoff for the distance between elution peaks required for
these proteins to be regarded as potentially interacting, we
constructed precision-recall curves using the CORUM database
(Ruepp et al, 2010). For this, we extracted the subset of the identi-
fied proteins which are in the CORUM database and compared the
interactions in the database to the interactions inferred from the
data when increasing the distance threshold between two elution
peaks from zero to the maximum observed distance. As threshold,
we chose the distance which resulted in a precision value of 0.5, as
this gave also a reasonable recall, thus allowing for identification of
potentially novel interactions.
Next, we extracted the interactions between all proteins with the
threshold established from the subset in CORUM. Applying this
threshold limited the interactions from all possible ~365,000 interac-
tions to 17,560. To increase the confidence further, we also required
an interaction to be found in at least two of the three biological
replicates in the same cell line, resulting in the final 3,739 reported
interactions. To group the list of identified binary interactions into
potential complexes, we used the Cytoscape plugin ClusterONE
(Nepusz et al, 2012) with default parameters except that we allowed
also for complexes composed of only two proteins resulting of the
grouping of the inferred interactions into 77 clusters representing
potential complexes.
Expanded View for this article is available online.
Acknowledgements
This work was supported by the German Research Foundation (DFG)
through the Emmy-Noether-and Heisenberg programs (TB), CRC 850,
projects B4 (TB) and B8 (JD), CRC 1140 (JD) and the Excellence Initiative of
the German Federal and State Governments through FRIAS (JD) and EXC
294 BIOSS (TB, JD). This study was also supported by the BMBF through e:
Bio 0316184D. KTGR is supported by the Danish Natural Sciences Research
Council. RFM and JD are supported by the Alexander von Humboldt
Foundation.
Author contributions
BD performed all experiments with the help of SK-P and CG. KTGR performed
data analysis, MR conducted BN–PAGE analysis and generated the MEF
system. RH generated cell lines. BD, MR, RFM, TB, and JD designed the study.
15
htt
p:/
/do
c.r
ero
.ch
All authors interpreted data and gave intellectual input. BD, TB, and JD wrote
the manuscript.
Conflict of interest
The authors declare that they have no conflict of interest.
References
Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates
RC, Proia DA (2014) Overcoming acquired BRAF inhibitor resistance in
melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer
Ther 13: 353 – 363
Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, Godfrey
JT, Nishimura K, Lynch KD, Mermel CH, Lockerman EL, Kalsy A, Gurski JM
Jr, Bahl S, Anderka K, Green LM, Lennon NJ, Huynh TG, Mino-Kenudson M,
Getz G et al (2015) Clinical acquired resistance to RAF inhibitor
combinations in BRAF-mutant colorectal cancer through MAPK pathway
alterations. Cancer Discov 5: 358 – 367
Baljuls A, Kholodenko BN, Kolch W (2013) It takes two to tango – signalling
by dimeric Raf kinases. Mol BioSyst 9: 551 – 558
Brady SC, Coleman ML, Munro J, Feller SM, Morrice NA, Olson MF (2009)
Sprouty2 association with B-Raf is regulated by phosphorylation and
kinase conformation. Cancer Res 69: 6773 – 6781
Brummer T, Naegele H, Reth M, Misawa Y (2003) Identification of novel ERK-
mediated feedback phosphorylation sites at the C-terminus of B-Raf.
Oncogene 22: 8823 – 8834
Brummer T, Martin P, Herzog S, Misawa Y, Daly RJ, Reth M (2006) Functional
analysis of the regulatory requirements of B-Raf and the B-Raf(V600E)
oncoprotein. Oncogene 25: 6262 – 6276
Callahan MK, Rampal R, Harding JJ, Klimek VM, Chung YR, Merghoub T,
Wolchok JD, Solit DB, Rosen N, Abdel-Wahab O, Levine RL, Chapman PB
(2012) Progression of RAS-mutant leukemia during RAF inhibitor
treatment. N Engl J Med 367: 2316 – 2321
Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S,
Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF
V600E mutation status by immunohistochemistry with a mutation-
specific monoclonal antibody. Acta Neuropathol 122: 11 – 19
Carlino MS, Kwan V, Miller DK, Saunders CA, Yip D, Nagrial AM, Tomlinson J,
Grimmond SM, Scolyer RA, Kefford RF, Biankin AV, Long GV (2015) New
RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK
inhibition for metastatic melanoma. J Clin Oncol 33: e52 – e56
Chang E, Park EY, Woo Y, Kang DH, Hwang YH, Ahn C, Park JH (2015)
Restoring multidrug resistance-associated protein 3 attenuates cell
proliferation in the polycystic kidney. Am J Physiol Renal Physiol 308:
F1004 – F1011
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer
R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T,
Schadendorf D, Ribas A, O’Day SJ, Sosman JA, Kirkwood JM, Eggermont AM
et al (2011) Improved survival with vemurafenib in melanoma with BRAF
V600E mutation. N Engl J Med 364: 2507 – 2516
Cheung M, Sharma A, Madhunapantula SV, Robertson GP (2008) Akt3 and
mutant V600E B-Raf cooperate to promote early melanoma development.
Cancer Res 68: 3429 – 3439
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD,
Della Pelle P, Dias-Santagata D, Hung KE, Flaherty KT, Piris A, Wargo JA,
Settleman J, Mino-Kenudson M, Engelman JA (2012) EGFR-mediated re-
activation of MAPK signaling contributes to insensitivity of BRAF mutant
colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov 2:
227 – 235
Cox J, Mann M (2008) MaxQuant enables high peptide identification rates,
individualized p.p.b.-range mass accuracies and proteome-wide protein
quantification. Nat Biotechnol 26: 1367 – 1372
Cseh B, Doma E, Baccarini M (2014) “RAF” neighborhood: protein-protein
interaction in the Raf/Mek/Erk pathway. FEBS Lett 588: 2398 – 2406
Dankort D, Filenova E, Collado M, Serrano M, Jones K, McMahon M (2007) A
new mouse model to explore the initiation, progression, and therapy of
BRAFV600E-induced lung tumors. Genes Dev 21: 379 – 384
Deswal S, Meyer A, Fiala GJ, Eisenhardt AE, Schmitt LC, Salek M, Brummer T,
Acuto O, Schamel WW (2013) Kidins220/ARMS associates with B-Raf and
the TCR, promoting sustained Erk signaling in T cells. J Immunol 190:
1927 – 1935
Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W (2002) Regulation of Raf-1
activation and signalling by dephosphorylation. EMBO J 21: 64 – 71
Dietrich S, Pircher A, Endris V, Peyrade F, Wendtner CM, Follows GA, Hullein J,
Jethwa A, Ellert E, Walther T, Liu X, Dyer MJ, Elter T, Brummer T, Zeiser R,
Hermann M, Herold M, Weichert W, Dearden C, Haferlach T et al (2016)
BRAF inhibition in hairy cell leukemia with low-dose vemurafenib. Blood
127: 2847 – 2855
Eisenhardt AE, Sprenger A, Roring M, Herr R, Weinberg F, Kohler M, Braun S,
Orth J, Diedrich B, Lanner U, Tscherwinski N, Schuster S, Dumaz N,
Schmidt E, Baumeister R, Schlosser A, Dengjel J, Brummer T (2016)
Phospho-proteomic analyses of B-Raf protein complexes reveal new
regulatory principles. Oncotarget 7: 26628 – 26652
Emuss V, Garnett M, Mason C, Marais R (2005) Mutations of C-RAF are rare
in human cancer because C-RAF has a low basal kinase activity compared
with B-RAF. Cancer Res 65: 9719 – 9726
Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R, Albert S,
Rajalingam K, Hekman M, Rapp UR (2009) Regulation of RAF activity by
14-3-3 proteins: RAF kinases associate functionally with both homo- and
heterodimeric forms of 14-3-3 proteins. J Biol Chem 284: 3183 – 3194
Freeman AK, Ritt DA, Morrison DK (2013) Effects of Raf dimerization and its
inhibition on normal and disease-associated Raf signaling. Mol Cell 49:
751 – 758
Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer
T, Sers C, Bluthgen N (2011) Strong negative feedback from Erk to Raf
confers robustness to MAPK signalling. Mol Syst Biol 7: 489
Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N (2006)
V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in
response to Hsp90 inhibitors. Proc Natl Acad Sci USA 103: 57 – 62
Haling JR, Sudhamsu J, Yen I, Sideris S, Sandoval W, Phung W, Bravo BJ,
Giannetti AM, Peck A, Masselot A, Morales T, Smith D, Brandhuber BJ,
Hymowitz SG, Malek S (2014) Structure of the BRAF-MEK complex reveals
a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell
26: 402 – 413
Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R,
Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris
S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS
et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK
pathway and enhance growth. Nature 464: 431 – 435
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M,
Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, Martin-Algarra S,
Karaszewska B, Mauch C, Chiarion-Sileni V, Martin AM, Swann S, Haney P,
Mirakhur B, Guckert ME, Goodman V et al (2012) Dabrafenib in BRAF-
mutated metastatic melanoma: a multicentre, open-label, phase 3
randomised controlled trial. Lancet 380: 358 – 365
16
htt
p:/
/do
c.r
ero
.ch
Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N,
Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-
dead BRAF and oncogenic RAS cooperate to drive tumor progression
through CRAF. Cell 140: 209 – 221
Herr R, Wohrle FU, Danke C, Berens C, Brummer T (2011) A novel MCF-10A
line allowing conditional oncogene expression in 3D culture. Cell Commun
Signal 9: 17
Herr R, Kohler M, Andrlova H, Weinberg F, Moller Y, Halbach S, Lutz L,
Mastroianni J, Klose M, Bittermann N, Kowar S, Zeiser R, Olayioye MA,
Lassmann S, Busch H, Boerries M, Brummer T (2015) B-Raf inhibitors
induce epithelial differentiation in BRAF-mutant colorectal cancer cells.
Cancer Res 75: 216 – 229
Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychene A (2007)
Differential regulation of B-raf isoforms by phosphorylation and
autoinhibitory mechanisms. Mol Cell Biol 27: 31 – 43
Holderfield M, Deuker MM, McCormick F, McMahon M (2014) Targeting RAF
kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev
Cancer 14: 455 – 467
Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJ, Kornev AP, Taylor
SS, Shaw AS (2013) Allosteric activation of functionally asymmetric RAF
kinase dimers. Cell 154: 1036 – 1046
Inoue S, Moriya M, Watanabe Y, Miyagawa-Tomita S, Niihori T, Oba D, Ono
M, Kure S, Ogura T, Matsubara Y, Aoki Y (2014) New BRAF knockin mice
provide a pathogenetic mechanism of developmental defects and a
therapeutic approach in cardio-facio-cutaneous syndrome. Hum Mol Genet
23: 6553 – 6566
Ishihama Y, Rappsilber J, Andersen JS, Mann M (2002) Microcolumns with
self-assembled particle frits for proteomics. J Chromatogr A 979: 233 – 239
Jaiswal RK, Weissinger E, Kolch W, Landreth GE (1996) Nerve growth factor-
mediated activation of the mitogen-activated protein (MAP) kinase
cascade involves a signaling complex containing B-Raf and HSP90. J Biol
Chem 271: 23626 – 23629
Karajannis MA, Legault G, Fisher MJ, Milla SS, Cohen KJ, Wisoff JH, Harter DH,
Goldberg JD, Hochman T, Merkelson A, Bloom MC, Sievert AJ, Resnick AC,
Dhall G, Jones DT, Korshunov A, Pfister SM, Eberhart CG, Zagzag D, Allen
JC (2014) Phase II study of sorafenib in children with recurrent or
progressive low-grade astrocytomas. Neuro Oncol 16: 1408 – 1416
Karoulia Z, Wu Y, Ahmed TA, Xin Q, Bollard J, Krepler C, Wu X, Zhang C,
Bollag G, Herlyn M, Fagin JA, Lujambio A, Gavathiotis E, Poulikakos PI
(2016) An integrated model of RAF inhibitor action predicts inhibitor
activity against oncogenic BRAF signaling. Cancer Cell 30: 485 – 498
Kirkwood KJ, Ahmad Y, Larance M, Lamond AI (2013) Characterization of
native protein complexes and protein isoform variation using size-
fractionation-based quantitative proteomics. Mol Cell Proteomics 12:
3851 – 3873
Köhler M, Röring M, Schorch B, Heilmann K, Stickel N, Fiala GJ, Schmitt LC,
Braun S, Ehrenfeld S, Uhl FM, Kaltenbacher T, Weinberg F, Herzog S,
Zeiser R, Schamel WW, Jumaa H, Brummer T (2016) Activation loop
phosphorylation regulates B-Raf in vivo and transformation by B-Raf
mutants. EMBO J 35: 143 – 161
Kristensen AR, Gsponer J, Foster LJ (2012) A high-throughput approach for
measuring temporal changes in the interactome. Nat Methods 9: 907 – 909
Lavoie H, Therrien M (2015) Regulation of RAF protein kinases in ERK
signalling. Nat Rev Mol Cell Biol 16: 281 – 298
Li L, Lou Z, Wang L (2011) The role of FKBP5 in cancer aetiology and
chemoresistance. Br J Cancer 104: 19 – 23
Lito P, Pratilas CA, Joseph EW, Tadi M, Halilovic E, Zubrowski M, Huang A, Wong
WL, Callahan MK, Merghoub T, Wolchok JD, de Stanchina E, Chandarlapaty
S, Poulikakos PI, Fagin JA, Rosen N (2012) Relief of profound feedback
inhibition of mitogenic signaling by RAF inhibitors attenuates their activity
in BRAFV600E melanomas. Cancer Cell 22: 668 – 682
Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA,
Smith PD, Cook SJ (2011) Amplification of the driving oncogene, KRAS or
BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal
cancer cells. Sci Signal 4: ra17
MacNicol MC, Muslin AJ, MacNicol AM (2000) Disruption of the 14-3-3
binding site within the B-Raf kinase domain uncouples catalytic activity
from PC12 cell differentiation. J Biol Chem 275: 3803 – 3809
Möller Y, Siegemund M, Beyes S, Herr R, Lecis D, Delia D, Kontermann R,
Brummer T, Pfizenmaier K, Olayioye MA (2014) EGFR-targeted TRAIL and a
smac mimetic synergize to overcome apoptosis resistance in KRAS mutant
colorectal cancer cells. PLoS ONE 9: e107165
Moriceau G, Hugo W, Hong A, Shi H, Kong X, Yu CC, Koya RC, Samatar AA,
Khanlou N, Braun J, Ruchalski K, Seifert H, Larkin J, Dahlman KB, Johnson DB,
Algazi A, Sosman JA, Ribas A, Lo RS (2015) Tunable-combinatorial
mechanisms of acquired resistance limit the efficacy of BRAF/MEK
cotargeting but result in melanoma drug addiction. Cancer Cell 27: 240 – 256
Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we
there yet? Clin Cancer Res 18: 64 – 76
Nepusz T, Yu H, Paccanaro A (2012) Detecting overlapping protein complexes
in protein-protein interaction networks. Nat Methods 9: 471 – 472
Papin C, Denouel A, Calothy G, Eychene A (1996) Identification of signalling
proteins interacting with B-Raf in the yeast two-hybrid system. Oncogene
12: 2213 – 2221
Pei H, Li L, Fridley BL, Jenkins GD, Kalari KR, Lingle W, Petersen G, Lou Z,
Wang L (2009) FKBP51 affects cancer cell response to chemotherapy by
negatively regulating Akt. Cancer Cell 16: 259 – 266
Phadke M, Gibney GT, Rich CJ, Fedorenko IV, Chen YA, Kudchadkar RR, Sondak
VK, Weber J, Messina JL, Smalley KS (2015) XL888 limits vemurafenib-
induced proliferative skin events by suppressing paradoxical MAPK
activation. J Invest Dermatol 135: 2542 – 2544
Polier S, Samant RS, Clarke PA, Workman P, Prodromou C, Pearl LH (2013)
ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-
Cdc37 system. Nat Chem Biol 9: 307 – 312
Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors
transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
Nature 464: 427 – 430
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H,
Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA,
Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG
et al (2011) RAF inhibitor resistance is mediated by dimerization of
aberrantly spliced BRAF(V600E). Nature 480: 387 – 390
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D,
Beijersbergen RL, Bardelli A, Bernards R (2012) Unresponsiveness of colon
cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Nature 483: 100 – 103
Pratilas CA, Taylor BS, Ye Q, Viale A, Sander C, Solit DB, Rosen N (2009)
(V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK
signaling and elevated transcriptional output of the pathway. Proc Natl
Acad Sci USA 106: 4519 – 4524
Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M (2009) A
dimerization-dependent mechanism drives RAF catalytic activation. Nature
461: 542 – 545
Rappsilber J, Mann M, Ishihama Y (2007) Protocol for micro-purification,
enrichment, pre-fractionation and storage of peptides for proteomics
using StageTips. Nat Protoc 2: 1896 – 1906
17
htt
p:/
/do
c.r
ero
.ch
Ritt DA, Monson DM, Specht SI, Morrison DK (2010) Impact of feedback
phosphorylation and Raf heterodimerization on normal and mutant B-Raf
signaling. Mol Cell Biol 30: 806 – 819
da Rocha Dias S, Friedlos F, Light Y, Springer C, Workman P, Marais R (2005)
Activated B-RAF is an Hsp90 client protein that is targeted by the
anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 65:
10686 – 10691
Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F
(2006) A phosphatase holoenzyme comprised of Shoc2/Sur8 and the
catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf
activity. Mol Cell 22: 217 – 230
Röring M, Brummer T (2012) Aberrant B-raf signaling in human cancer –
10 years from bench to bedside. Crit Rev Oncog 17: 97 – 121
Röring M, Herr R, Fiala GJ, Heilmann K, Braun S, Eisenhardt AE, Halbach S,
Capper D, von Deimling A, Schamel WW, Saunders DN, Brummer T (2012)
Distinct requirement for an intact dimer interface in wild-type, V600E and
kinase-dead B-Raf signalling. EMBO J 31: 2629 – 2647
Ruepp A, Waegele B, Lechner M, Brauner B, Dunger-Kaltenbach I, Fobo G,
Frishman G, Montrone C, Mewes HW (2010) CORUM: the comprehensive
resource of mammalian protein complexes–2009. Nucleic Acids Res 38:
D497 –D501
Rushworth LK, Hindley AD, O’Neill E, Kolch W (2006) Regulation and role of
Raf-1/B-Raf heterodimerization. Mol Cell Biol 26: 2262 – 2272
Samatar AA, Poulikakos PI (2014) Targeting RAS-ERK signalling in cancer:
promises and challenges. Nat Rev Drug Discov 13: 928 – 942
Shen CH, Yuan P, Perez-Lorenzo R, Zhang Y, Lee SX, Ou Y, Asara JM,
Cantley LC, Zheng B (2013) Phosphorylation of BRAF by AMPK
impairs BRAF-KSR1 association and cell proliferation. Mol Cell 52:
161 – 172
Shevchenko A, Tomas H, Havlis J, Olsen JV, Mann M (2006) In-gel digestion
for mass spectrometric characterization of proteins and proteomes. Nat
Protoc 1: 2856 – 2860
Sievert AJ, Lang SS, Boucher KL, Madsen PJ, Slaunwhite E, Choudhari N, Kellet
M, Storm PB, Resnick AC (2013) Paradoxical activation and RAF inhibitor
resistance of BRAF protein kinase fusions characterizing pediatric
astrocytomas. Proc Natl Acad Sci USA 110: 5957 – 5962
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A,
Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB,
Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR (2012) Tumour
micro-environment elicits innate resistance to RAF inhibitors through HGF
secretion. Nature 487: 500 – 504
Sturm OE, Orton R, Grindlay J, Birtwistle M, Vyshemirsky V, Gilbert D, Calder
M, Pitt A, Kholodenko B, Kolch W (2010) The mammalian MAPK/ERK
pathway exhibits properties of a negative feedback amplifier. Sci Signal 3:
ra90
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X,
Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang
H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M et al (2012) RAS
mutations in cutaneous squamous-cell carcinomas in patients treated
with BRAF inhibitors. N Engl J Med 366: 207 – 215
Swamy M, Siegers GM, Minguet S, Wollscheid B, Schamel WW (2006) Blue
native polyacrylamide gel electrophoresis (BN-PAGE) for the identification
and analysis of multiprotein complexes. Sci STKE 2006: pl4
Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J,
Simonovic M, Roth A, Santos A, Tsafou KP, Kuhn M, Bork P, Jensen LJ, von
Mering C (2015) STRING v10: protein-protein interaction networks,
integrated over the tree of life. Nucleic Acids Res 43: D447 –D452
Thevakumaran N, Lavoie H, Critton DA, Tebben A, Marinier A, Sicheri F,
Therrien M (2015) Crystal structure of a BRAF kinase domain monomer
explains basis for allosteric regulation. Nat Struct Mol Biol 22: 37 – 43
Tsavachidou D, Coleman ML, Athanasiadis G, Li S, Licht JD, Olson MF, Weber
BL (2004) SPRY2 is an inhibitor of the ras/extracellular signal-regulated
kinase pathway in melanocytes and melanoma cells with wild-type BRAF
but not with the V599E mutant. Cancer Res 64: 5556 – 5559
Turski ML, Vidwans SJ, Janku F, Garrido-Laguna I, Munoz J, Schwab R,
Subbiah V, Rodon J, Kurzrock R (2016) Genomically driven tumors and
actionability across histologies: BRAF-mutant cancers as a paradigm. Mol
Cancer Ther 15: 533 – 547
Vaughan CK, Gohlke U, Sobott F, Good VM, Ali MM, Prodromou C, Robinson
CV, Saibil HR, Pearl LH (2006) Structure of an Hsp90-Cdc37-Cdk4 complex.
Mol Cell 23: 697 – 707
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L,
Newman J, Reczek EE, Weissleder R, Jacks T (2007) Restoration of p53
function leads to tumour regression in vivo. Nature 445: 661 – 665
Vizcaino JA, Csordas A, del-Toro N, Dianes JA, Griss J, Lavidas I, Mayer G,
Perez-Riverol Y, Reisinger F, Ternent T, Xu QW, Wang R, Hermjakob H
(2016) 2016 update of the PRIDE database and its related tools. Nucleic
Acids Res 44: D447 –D456
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM,
Marshall CJ, Springer CJ, Barford D, Marais R (2004) Mechanism of
activation of the RAF-ERK signaling pathway by oncogenic mutations of
B-RAF. Cell 116: 855 – 867
Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang
X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B,
Liu L, Adnane L, Lynch M, Auclair D, Taylor I et al (2004) BAY 43-9006
exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/
ERK pathway and receptor tyrosine kinases involved in tumor progression
and angiogenesis. Cancer Res 64: 7099 – 7109
Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus
R, Hutter B, Frohling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS,
Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R (2014) BRAF inhibitor-
associated ERK activation drives development of chronic lymphocytic
leukemia. J Clin Invest 124: 5074 – 5084
Zhang BH, Guan KL (2000) Activation of B-Raf kinase requires
phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19:
5429 – 5439
18
htt
p:/
/do
c.r
ero
.ch
